Sarepta Therapeutics Inc (SRPT)

43.41
NASDAQ : Health Care
Prev Close 40.93
Day Low/High 41.49 / 44.07
52 Wk Low/High 22.61 / 63.73
Avg Volume 2.16M
Exchange NASDAQ
Shares Outstanding 54.96M
Market Cap 2.25B
EPS -5.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Sarepta Therapeutics And Clinigen Launch A Managed Access Program To Treat Patients With Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping

Sarepta Therapeutics And Clinigen Launch A Managed Access Program To Treat Patients With Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping

The MAP will be available to a limited number of patients who meet pre-specified medical criteria and can secure funding

Sarepta Therapeutics And BioMarin Pharmaceutical Inc. Announce Execution Of A Global Settlement And A License Agreement Resolving Exon Skipping Patent Litigation

Sarepta Therapeutics And BioMarin Pharmaceutical Inc. Announce Execution Of A Global Settlement And A License Agreement Resolving Exon Skipping Patent Litigation

Agreement terms resolve global patent proceedings regarding Sarepta's sale of EXONDYS 51® (eteplirsen) and future Duchenne muscular dystrophy (DMD) exon-skipping products

Biotech Movers: Akebia Shares Down After Pricing Stock Offering

Biotech Movers: Akebia Shares Down After Pricing Stock Offering

Akebia Therapeutics, Sarepta Therapeutics and Esperion Therapeutics were among the biotech stock movers in premarket trading on June 29.

Sarepta Therapeutics Appoints Douglas S. Ingram As President And Chief Executive Officer

Mr. Ingram was the President of Allergan, Inc.

Dow and S&P 500 Dive Further From Records as Oil Price Rout Rages On

Dow and S&P 500 Dive Further From Records as Oil Price Rout Rages On

The S&P 500 and Dow slip on a crude oil slump.

Energy Sector Pressures the Dow and S&P 500 as Crude Selloff Steepens

Energy Sector Pressures the Dow and S&P 500 as Crude Selloff Steepens

Stocks are mixed as energy lags, health care leads.

Scott+Scott, Attorneys At Law, LLP Reminds Investors Of Its Investigation Of Sarepta Therapeutics, Inc.

Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is investigating Sarepta Therapeutics, Inc.

Sirius XM Radio, Shopify, Teledoc, Tyson Foods: 'Mad Money' Lightning Round

Sirius XM Radio, Shopify, Teledoc, Tyson Foods: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Sirius XM Radio, Shopify, Teledoc, Sarepta Therapeutics, Pilgrim's Pride.

Brand Loyalty Elusive for Apparel Retailers: Cramer's 'Mad Money' Recap (Tuesday 6/6/17)

Brand Loyalty Elusive for Apparel Retailers: Cramer's 'Mad Money' Recap (Tuesday 6/6/17)

It's not about fashion missteps, says Jim Cramer. Who cares what the products look like if there's no one in the stores?

Biotech Needs a Shot in the Arm

Biotech Needs a Shot in the Arm

But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.

Biotech Needs a Shot in the Arm

Biotech Needs a Shot in the Arm

But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.

Big Fund Managers Offer Up Stock Pick Ideas

Big Fund Managers Offer Up Stock Pick Ideas

Hedge fund managers offer up some investment ideas.

Liking the Look of Some of These Pullbacks

Liking the Look of Some of These Pullbacks

This corrective action has me feeling optimistic about some new opportunities.

Sarepta Therapeutics May Attract Activist Attention

Sarepta Therapeutics May Attract Activist Attention

Large pharmaceutical companies could be interested in buying the drug company, but even if a deal isn't forthcoming an activist investor could seek to elect directors and make one happen

Under the Surface, There Are Warnings in This Market

Under the Surface, There Are Warnings in This Market

Small caps are down 0.12% despite the strength in the Nasdaq ETF.

Sarepta CEO Leaves Along With a Sanofi Director, So Let's Speculate About a Possible Deal

Sarepta CEO Leaves Along With a Sanofi Director, So Let's Speculate About a Possible Deal

Sarepta CEO Ed Kaye said he's stepping down.

Biotech Movers: CEO Exit, Tea Leaf Reading Prompts Surge in Sarepta Shares

Biotech Movers: CEO Exit, Tea Leaf Reading Prompts Surge in Sarepta Shares

Sarepta Therapeutics and Vertex Pharmaceuticals and Endo Pharmaceuticals were among the biotech stock movers Friday morning.

Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal

Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal

The timing of these two departures could be coincidental and mean nothing, or they might signal Sanofi's interest in acquiring Sarepta.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.